[Managing patients with therapeutic antibodies in odontostomatology].

[1]  E. Machtei,et al.  Periodontal condition of patients with autoimmune diseases and the effect of anti-tumor necrosis factor-α therapy. , 2013, Journal of periodontology.

[2]  O. Beirne,et al.  The relationship of denosumab pharmacology and osteonecrosis of the jaws. , 2012, Oral surgery, oral medicine, oral pathology and oral radiology.

[3]  J. Villano,et al.  Bevacizumab-Induced Oral Mucositis in Background of Cutaneous Plaque-Type Psoriasis , 2012, The Annals of pharmacotherapy.

[4]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Y. Okamoto,et al.  Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review , 2012, Journal of allergy.

[6]  M. Lacouture,et al.  Characteristics of oral mucosal events related to bevacizumab treatment. , 2012, The oncologist.

[7]  M. Gershwin,et al.  Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. , 2011, Journal of autoimmunity.

[8]  B. Edwards,et al.  Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. , 2011, Journal of the American Dental Association.

[9]  Moses Rodriguez,et al.  Autoantibodies with enzymatic properties in human autoimmune diseases. , 2011, Journal of autoimmunity.

[10]  J. Epstein,et al.  Oral complications of targeted cancer therapies: a narrative literature review. , 2011, Oral oncology.

[11]  P. Emery,et al.  New therapies in the management of rheumatoid arthritis , 2011, Current opinion in rheumatology.

[12]  D. Perrett,et al.  Involvement of Autoimmunity in the Pathogenesis of Aggressive Periodontitis , 2010, Journal of dental research.

[13]  N. Robert,et al.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[14]  J. Gea-Banacloche.  Rituximab-associated infections. , 2010, Seminars in hematology.

[15]  E. Machtei,et al.  Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis. , 2009, Journal of periodontology.

[16]  M. Wislez,et al.  Bevacizumab et actes invasifs : recommandations pratiques , 2009 .

[17]  G. Peoples,et al.  Overcoming Cancer Immune Tolerance and Escape , 2009, Clinical Cancer Research.

[18]  J. Pers,et al.  Anti–TNF‐α Immunotherapy Is Associated With Increased Gingival Inflammation Without Clinical Attachment Loss in Subjects With Rheumatoid Arthritis , 2008 .

[19]  P. Bartold,et al.  Inter-relationships between rheumatoid arthritis and periodontal disease. A review. , 2003, Journal of clinical periodontology.

[20]  D. Chaplin.  Overview of the immune response. , 2003, The Journal of allergy and clinical immunology.

[21]  P. Chames,et al.  THEMED SECTION: VECTOR DESIGN AND DRUG DELIVERY REVIEW Therapeutic antibodies: successes, limitations and hopes for the future , 2022 .